Tafasitamab Antibody

SKU: orb1980313

Description

Tafasitamab is an Fc-engineered, humanized monoclonal antibody directed against CD19. It is a research tool for investigating B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 1422527-84-1
• MW: 147.41 kDa
• Purity: 99.3% (SEC-HPLC)
• Target: Apoptosis,Immunology/Inflammation related

Bioactivity

• In Vivo:
  In a xenograft tumor model of disseminated BL mice, tafasitamab (2.5 μg/kg, once on day 1) inhibited lymphoma growth.
• In Vitro:
  In an E/T ratio-dependent manner, tafasitamab (XmAb5574) induced cytotoxicity to Mino and Jeko (MCL) cell lines. It also increased antibody-dependent cellular phagocytosis (ADCP) and antiproliferative activity. Additionally, tafasitamab (XmAb5574) can enhance the anti-proliferative activity induced by caspase-mediated apoptosis.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, CD19, MOR 00208, MOR00208, MOR-00208, Immunology related, Immunologyrelated, Inflammationrelated, Inflammation related, XmAb5574, Tafasitamab, Tafasitamab-cxix

Quick Database Links

Gene Symbol

Apoptosis,Immunology/Inflammation related